诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09969 诺诚健华

已收盘 09-09 16:08:06

14.480

-0.280

-1.90%

最高14.760	最低14.240	成交量600.90万
今开14.760	昨收14.760	日振幅3.52%
总市值255.86亿	流通市值216.33亿	总股本17.67亿
成交额8,665万	换手率0.40%	流通股本14.94亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09969","market":"HK","secType":"STK","nameCN":"诺诚健华","latestPrice":14.48,"timestamp":1788941286010,"preClose":14.76,"halted":0,"volume":6009000,"delay":0,"changeRate":-0.018970189701896976,"floatShares":1494000000,"shares":1767000000,"eps":0.4444012234334561,"marketStatus":"已收盘","change":-0.28,"latestTime":"09-09 16:08:06","open":14.76,"high":14.76,"low":14.24,"amount":86645860,"amplitude":0.03523,"askPrice":14.48,"askSize":30000,"bidPrice":14.47,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":0.5910278986746137,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789003800000},"marketStatusCode":5,"adr":0,"listingDate":1584892800000,"exchange":"SEHK","adjPreClose":14.76,"openAndCloseTimeList":[[1788917400000,1788926400000],[1788930000000,1788940800000]],"volumeRatio":0.784182,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"诺诚健华","latestPrice":28.89,"timestamp":1788937200000,"preClose":30.47,"halted":0,"volume":10873700,"delay":0,"premium":"-57.14"}},"requestUrl":"/m/hq/s/09969/wiki","defaultTab":"wiki","newsList":[{"id":"2665632198","title":"诺诚健华（688428）披露收购控股子公司剩余股权进展公告，9月8日股价下跌1.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2665632198","media":"证券之星","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665632198?lang=zh_cn&edition=full","pubTime":"2026-09-08 17:59","pubTimestamp":1788861568,"startTime":"0","endTime":"0","summary":"截至2026年9月8日收盘，诺诚健华报收于30.47元，较前一交易日下跌1.23%，最新总市值为539.05亿元。诺诚健华医药有限公司于2026年9月8日发布《关于收购控股子公司剩余股权的进展公告》。截至本公告披露日，第一次转让3.5%股权已通过产权交易所公开挂牌竞价完成，北京诺诚健华成功摘牌并完成交割，成交价为23,816.8万元，工商变更已办理完毕。本次转让后，北京诺诚健华持有广州诺诚健华96.5%股权，高新科控仍持有3.5%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090800028538.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","688428","09969","BK1161","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183111764","title":"诺诚健华（09969）首轮增持广州子公司股权完成　耗资2.38亿元持股升至96.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1183111764","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183111764?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:35","pubTimestamp":1788773745,"startTime":"0","endTime":"0","summary":"2026年9月8日，诺诚健华医药有限公司发布公告称，其全资子公司北京诺诚健华医药科技有限公司已完成广州诺诚健华医药科技有限公司3.5%股权的受让及工商变更登记。本次受让价款为23,816.8万元，折合约2.38亿元。交易完成后，北京诺诚健华对广州诺诚健华的持股比例由93%提升至96.5%，高新科控持股降至3.5%。诺诚健华将按照产权交易所相关规定继续参与第二次挂牌竞价。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665365872","title":"每周股票复盘：诺诚健华（688428）当月股份无变动","url":"https://stock-news.laohu8.com/highlight/detail?id=2665365872","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665365872?lang=zh_cn&edition=full","pubTime":"2026-09-06 01:18","pubTimestamp":1788628692,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘，诺诚健华报收于31.71元，较上周的29.04元上涨9.19%。本周，诺诚健华9月4日盘中最高价报31.86元。本周关注点公司公告汇总：诺诚健华当月股份无变动，公众持股量符合上市规则要求。公司公告汇总诺诚健华医药有限公司截至2026年8月31日，法定注册资本为50,000美元，已发行普通股总数为1,496,284,235股，其中港股1,493,798,235股，科创板人民币股272,822,767股，库存股2,486,000股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090600000154.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","BK1161","BK0239","BK1574","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664610382","title":"瞄准银屑病市场，诺诚健华ICP-488值多少钱？","url":"https://stock-news.laohu8.com/highlight/detail?id=2664610382","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664610382?lang=zh_cn&edition=full","pubTime":"2026-09-04 15:23","pubTimestamp":1788506580,"startTime":"0","endTime":"0","summary":"患者总人数方面，ICP-488核心覆盖中重度斑块状银屑病适应症，根据公开行业数据与诺诚健华官方披露，中国银屑病患者总规模约866万人，且呈持续上升趋势。其中约32%的患者为中重度斑块状银屑病，具备系统治疗临床需求，对应目标患者总人数约280万人。整体来看，ICP-488采用规范的RCT试验设计，疗效达到现有标准治疗的先进水平，优于常规非劣效品种，因此临床数据质量系数取0.80。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-09-04/doc-iniqryes4101624.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","BK1161","688428","BK1574","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156777574","title":"异动解读｜诺诚健华盘中上涨5.48%，多家机构给予买入评级叠加半年报业绩亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=1156777574","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156777574?lang=zh_cn&edition=full","pubTime":"2026-09-04 14:15","pubTimestamp":1788502559,"startTime":"0","endTime":"0","summary":"9月4日，诺诚健华港股盘中上涨5.48%，报15.58港元，成交额1.55亿港元。消息面上，近期多家机构密集看好该股。高盛将其目标价上调至22.71港元并维持买入评级，指出核心产品奥布替尼二季度销售同比增长37%表现强劲；长城国瑞证券、国金证券亦给予买入评级，机构90日目标均价36.73元人民币。此外，公司半年报显示上半年营收11.37亿元，同比增长55.46%，归母净利润2.46亿元，同比扭亏为盈，二季度单季净利润同比增长392.43%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"诺诚健华盘中上涨，机构买入评级叠加业绩亮眼","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664587090","title":"诺诚健华（688428）披露证券变动月报表，9月3日股价上涨6.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664587090","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664587090?lang=zh_cn&edition=full","pubTime":"2026-09-03 22:10","pubTimestamp":1788444627,"startTime":"0","endTime":"0","summary":"截至2026年9月3日收盘，诺诚健华报收于30.8元，较前一交易日上涨6.83%，最新总市值为544.88亿元。近日，诺诚健华医药有限公司发布港股公告《证券变动月报表》。公告显示，截至2026年8月31日，公司法定注册资本为50,000美元，已发行普通股总数为1,496,284,235股，其中港股1,493,798,235股，科创板人民币股272,822,767股，库存股2,486,000股。存在三项人民币股股权激励计划，涉及可能发行的限制性股票总额合计约2,468,500股、9,759,450股及7,999,800股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300042237.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","BK1161","BK0239","BK1574","161027","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112022805","title":"诺诚健华8月股份变动月报：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1112022805","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112022805?lang=zh_cn&edition=full","pubTime":"2026-09-03 17:02","pubTimestamp":1788426143,"startTime":"0","endTime":"0","summary":"诺诚健华医药有限公司于2026年9月3日发布2026年8月股份变动月报。报告显示，截至2026年8月31日，公司注册股本维持25,000,000,000股普通股不变，面值均为每股0.000002美元，总注册股本约为50,000美元。报告期内，诺诚健华于香港联交所上市的普通股已发行股份数为1,493,798,235股，库存股数量为2,486,000股，两项合计1,496,284,235股，与上月底持平。报告期内未发生新增发行、购回或注销股份的情况。公司在本月确认已持续符合相关法律法规及香港联交所主板上市规则所要求的公众持股量。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664203848","title":"9月3日诺诚健华涨6.83%，富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2664203848","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664203848?lang=zh_cn&edition=full","pubTime":"2026-09-03 16:38","pubTimestamp":1788424691,"startTime":"0","endTime":"0","summary":"证券之星消息，9月3日诺诚健华涨6.83%，收盘报30.8元，换手率6.06%，成交量16.52万手，成交额4.94亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共35家，其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为28.98亿元，最新净值3.2949，较上一交易日下跌0.37%，近一年下跌10.28%。富国精准医疗混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300030084.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688428","BK0239","09969","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664820566","title":"诺诚健华涨6.83%，长城国瑞证券三日前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2664820566","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664820566?lang=zh_cn&edition=full","pubTime":"2026-09-03 16:38","pubTimestamp":1788424686,"startTime":"0","endTime":"0","summary":"今日诺诚健华涨6.83%，收盘报30.8元。2026年8月31日，长城国瑞证券研究员胡晨曦发布了对诺诚健华的研报《药品收入持续高增，自免管线兑现在即》，该研报对诺诚健华给出“买入”评级。因此，我们维持其“买入”评级。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为国海证券的孔维崎、周小刚。诺诚健华个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300030082.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","09969","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663502955","title":"大行评级丨高盛：上调诺诚健华目标价至22.71港元，未来12至18个月催化剂众多","url":"https://stock-news.laohu8.com/highlight/detail?id=2663502955","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663502955?lang=zh_cn&edition=full","pubTime":"2026-08-31 10:47","pubTimestamp":1788144425,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1161","BK1574","BK0239","688428","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662050217","title":"高盛：诺诚健华(09969)奥布替尼次季销售强劲 目标价升至22.71港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662050217","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662050217?lang=zh_cn&edition=full","pubTime":"2026-08-28 16:37","pubTimestamp":1787906260,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，高盛发布研报称，将诺诚健华2026至2028年每股盈利预测由0.15、0.05及0.32元人民币上调至0.16、0.08及0.37元人民币，目标价由20.54港元上调至22.71港元，维持“买入”评级。诺诚健华第二季度产品销售额年度同比增长37%，大致符合预期，受惠于核心产品奥布替尼持续强劲增长，以及新上市的坦昔妥单抗及Zurletrectinib的初步贡献。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1487898.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688428","09969","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662674157","title":"股市必读：诺诚健华新发布《诺诚健华医药有限公司董事会薪酬委员会关于公司2024年科创板限制性股票激励计划预留授予部分第一个归属期归属名单的核查意见》","url":"https://stock-news.laohu8.com/highlight/detail?id=2662674157","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662674157?lang=zh_cn&edition=full","pubTime":"2026-08-27 03:35","pubTimestamp":1787772921,"startTime":"0","endTime":"0","summary":"公司公告汇总诺诚健华医药有限公司董事会薪酬委员会关于公司2024年科创板限制性股票激励计划预留授予部分第一个归属期归属名单的核查意见董事会薪酬委员会核查确认86名激励对象符合《管理办法》《上市规则》等规定的资格条件，归属条件已成就，同意本次归属名单。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700007832.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK1161","09939","159938","BK0239","BK1574","09969","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662762889","title":"国金证券：给予诺诚健华买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2662762889","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662762889?lang=zh_cn&edition=full","pubTime":"2026-08-26 12:28","pubTimestamp":1787718515,"startTime":"0","endTime":"0","summary":"国金证券股份有限公司甘坛焕,刘创近期对诺诚健华进行研究并发布了研究报告《商业化收入亮眼，管线里程碑密集》，给予诺诚健华买入评级。　　经营分析　　26H1公司达成多项里程碑。对应PE分别为107.79/291.60/55.75倍，维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有4家机构给出评级，买入评级3家，增持评级1家；过去90天内机构目标均价为36.73。本文数据来源于国金证券股份有限公司，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600026586.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662758546","title":"诺诚健华（688428）发布2024年科创板限制性股票激励计划预留授予部分第一个归属期归属名单，8月25日股价上涨4.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662758546","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662758546?lang=zh_cn&edition=full","pubTime":"2026-08-25 22:05","pubTimestamp":1787666700,"startTime":"0","endTime":"0","summary":"截至2026年8月25日收盘，诺诚健华报收于28.7元，较前一交易日上涨4.21%，最新总市值为507.73亿元。该股当日开盘27.7元，最高28.84元，最低27.12元，成交额达3.32亿元，换手率为4.37%。公司于2026年8月25日召开董事会，审议通过《2024年科创板限制性股票激励计划预留授予部分第一个归属期符合归属条件》的议案，认为归属条件已成就，同意为86名激励对象办理归属手续，可归属数量为581,137股。表决结果均为7票赞成，0票反对，0票弃权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500050090.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0239","688428","09969","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662737912","title":"诺诚健华：8月25日召开业绩说明会，投资者参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2662737912","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662737912?lang=zh_cn&edition=full","pubTime":"2026-08-25 21:07","pubTimestamp":1787663265,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年8月25日诺诚健华发布公告称公司于2026年8月25日召开业绩说明会。2026年上半年，公司营业收入持续实现强劲增长，实现营业总收入人民币11.37亿元，同比增长55.46%,上半年继续保持盈利。诺诚健华主营业务：主要从事生物医药研发、生产和商业化。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500048142.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688428","BK1574","09969","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194610141","title":"诺诚健华(09969)：预留限制性股票首个归属期达标 58.11万股将于登记后划转","url":"https://stock-news.laohu8.com/highlight/detail?id=1194610141","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194610141?lang=zh_cn&edition=full","pubTime":"2026-08-25 18:28","pubTimestamp":1787653698,"startTime":"0","endTime":"0","summary":"2026年8月26日，诺诚健华医药有限公司公告称，其董事会于2026年8月25日审议通过《2024年科创板限制性股票激励计划预留授予部分第一个归属期符合归属条件》的议案，确认首个归属期已满足全部归属条件，将为86名激励对象办理共计581,137股限制性股票的归属手续，归属股份登记完成当日即为归属日。公司表示，本次限制性股票归属产生的相关股份支付费用已按企业会计准则在等待期内分期计入成本费用，对当前财务状况和经营成果不构成重大影响。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662738086","title":"诺诚健华上半年扭亏为盈，高管强调BD会审慎筛选合作方","url":"https://stock-news.laohu8.com/highlight/detail?id=2662738086","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662738086?lang=zh_cn&edition=full","pubTime":"2026-08-25 17:49","pubTimestamp":1787651340,"startTime":"0","endTime":"0","summary":"“公司收入来自商业化销售叠加BD双驱动，公司对2026年持续盈利充满信心，BD（业务拓展）交易谈判会审慎筛选优质合作方。”在8月25日的2026上半年业绩说明会上，诺诚健华（9969.HK；688428.SH）联合创始人、董事长兼首席执行官崔霁松表达了上述观点。诺诚健华成立于2015年，2020年在港交所上市，2022年登陆科创板，2025年公司首次实现年度盈利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608253852971124.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608253852971124.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","688428","BK1574","BD","BK1161","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138332249","title":"异动解读｜诺诚健华盘中上涨5.08%，中期业绩扭亏为盈商业化产品强劲增长","url":"https://stock-news.laohu8.com/highlight/detail?id=1138332249","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138332249?lang=zh_cn&edition=full","pubTime":"2026-08-25 13:33","pubTimestamp":1787636004,"startTime":"0","endTime":"0","summary":"8月25日，诺诚健华盘中上涨5.08%，报14.49港元，成交额6063.84万港元。消息面上，公司于8月24日披露中期业绩，上半年实现收入11.37亿元，同比增长55.46%；归母净利润2.46亿元，同比扭亏为盈；经调整利润约2.77亿元。其中Q2单季归母净利润同比增长392.43%。药物销售收入9.18亿元，同比增长43.2%，主要来自BTK抑制剂奥布替尼持续放量及坦昔妥单抗、佐来曲替尼新上市贡献。公司毛利率达89.54%，现金余额84.31亿元，多元化管线布局持续推进。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"诺诚健华盘中上涨，扭亏为盈商业化提速","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662783526","title":"港股异动 | 诺诚健华(09969.HK)涨超4% 商业化产品强劲增长叠加BD兑现 上半年同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2662783526","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662783526?lang=zh_cn&edition=full","pubTime":"2026-08-25 11:42","pubTimestamp":1787629352,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1161","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662082122","title":"图解诺诚健华中报：第二季度单季净利润同比增长392.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662082122","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662082122?lang=zh_cn&edition=full","pubTime":"2026-08-25 01:33","pubTimestamp":1787592817,"startTime":"0","endTime":"0","summary":"证券之星消息，诺诚健华2026年中报显示，上半年度公司主营收入11.37亿元，同比上升55.46%；归母净利润2.46亿元，同比上升918.69%；扣非净利润1.87亿元，同比上升327.38%；其中2026年第二季度，公司单季度主营收入6.08亿元，同比上升73.75%；单季度归母净利润1.41亿元，同比上升392.43%；单季度扣非净利润9113.65万元，同比上升208.67%；负债率31.48%，投资收益2121.74万元，财务费用-3282.39万元，毛利率89.54%。财报数据概要请见下图:本文数据来源于诺诚健华2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500004378.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","688428"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"https://cn.innocarepharma.com","stockEarnings":[{"period":"1week","weight":0.0498},{"period":"1month","weight":0.0322},{"period":"3month","weight":0.4206},{"period":"6month","weight":0.253},{"period":"1year","weight":-0.1768},{"period":"ytd","weight":0.2}],"compareEarnings":[{"period":"1week","weight":-0.0005},{"period":"1month","weight":-0.0137},{"period":"3month","weight":0.0373},{"period":"6month","weight":-0.0155},{"period":"1year","weight":-0.0124},{"period":"ytd","weight":-0.0122}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"诺诚健华医药有限公司是一家主要从事生物医药研发、生产和商业化的中国公司。该公司专注于肿瘤和自身免疫性疾病等存在未满足临床需求的领域。该公司的主要产品管线包括奥布替尼、Tafasitamab、ICP-490、ICP-B02、ICP-248、ICP-B05、ICP-332、ICP-488、ICP-192、ICP-723、ICP-033和ICP-189等。其产品主要用于治疗血液瘤、实体瘤和自身免疫疾病。该公司还在开发用于治疗由T细胞功能异常所导致的自身免疫性疾病的产品。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.103999},{"month":2,"riseRate":0.666667,"avgChangeRate":0.128923},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.010195},{"month":4,"riseRate":0.714286,"avgChangeRate":0.102464},{"month":5,"riseRate":0.142857,"avgChangeRate":-0.059233},{"month":6,"riseRate":0.857143,"avgChangeRate":0.113731},{"month":7,"riseRate":0.571429,"avgChangeRate":0.05509},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.06378},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.016444},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.033299},{"month":11,"riseRate":0.833333,"avgChangeRate":0.100833},{"month":12,"riseRate":0.5,"avgChangeRate":-0.012645}],"exchange":"SEHK","name":"诺诚健华","nameEN":"INNOCARE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺诚健华(09969)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺诚健华,09969,诺诚健华股票,诺诚健华股票老虎,诺诚健华股票老虎国际,诺诚健华行情,诺诚健华股票行情,诺诚健华股价,诺诚健华股市,诺诚健华股票价格,诺诚健华股票交易,诺诚健华股票购买,诺诚健华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺诚健华(09969)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}